***Amendments to the Specification***

Please replace paragraph **[0023]** with the following:

**[0023]** ~~Figure 1~~ Figure 1A-C shows the cDNA sequence (SEQ ID NO:1) and the corresponding deduced amino acid sequence (SEQ ID NO:2) of the G-protein receptor of the present invention which has been putatively identified as a platelet-activating factor receptor. The standard one-letter abbreviation for amino acids is used. Sequencing was performed using a 373 Automated DNA sequencer (Applied Biosystems, Inc.).

Please replace paragraph **[0025]** with the following:

**[0025]** In accordance with an aspect of the present invention, there is provided an isolated nucleic acid (polynucleotide) which encodes for the mature polypeptide having the deduced amino acid sequence of ~~Figure 1~~ Figure 1A-C (SEQ ID NO:2) or for the mature polypeptide encoded by the cDNA of the clone HTNAD29 deposited as ATCC Deposit No. 97184 on June 1, 1995, the with ATCC, 10801 University Boulevard, Manassas, Virginia 20110-2209. Since the strain referred to is being maintained under the terms of the Budapest Treaty, each will be made available to a patent office signatory to the Budapest Treaty.

Please replace paragraphs **[0027-0028]** with the following:

**[0027]** The polynucleotide of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the mature polypeptide may be identical to the coding sequence shown in ~~Figure 1~~ Figure 1A-C (SEQ ID NO:1) or that of the deposited clone or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same mature polypeptide as the DNA of ~~Figure 1~~ Figure 1A-C (SEQ ID NO:1) or the deposited cDNA.

**[0028]** The polynucleotide which encodes for the mature polypeptide of ~~Figure 1~~ Figure 1A-C (SEQ ID NO:2) or for the mature polypeptide encoded by the deposited cDNA may include: only the coding sequence for the mature polypeptide; the coding sequence for the mature polypeptide and additional coding sequence; the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequence, such as introns or non-coding sequence 5' and/or 3' of the coding sequence for the mature polypeptide.

Please replace paragraph **[0030-0032]** with the following:

**[0030]** The present invention further relates to variants of the hereinabove described polynucleotides which encode for fragments, analogs and derivatives of the polypeptide having the deduced amino acid sequence of ~~Figure 1~~ Figure 1A-C (SEQ ID NO:2) or the polypeptide encoded by the cDNA of the deposited clone. The variant of the polynucleotide may be a naturally occurring allelic variant of the polynucleotide or a non-naturally occurring variant of the polynucleotide.

**[0031]** Thus, the present invention includes polynucleotides encoding the same mature polypeptide as shown in ~~Figure 1~~ Figure 1A-C (SEQ ID NO:2) or the same mature polypeptide encoded by the cDNA of the deposited clone as well as variants of such polynucleotides which variants encode for a fragment, derivative or analog of the polypeptide of ~~Figure 1~~ Figure 1A-C (SEQ ID NO:2) or the polypeptide encoded by the cDNA of the deposited clone. Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.

**[0032]** As hereinabove indicated, the polynucleotide may have a coding sequence which is a naturally occurring allelic variant of the coding sequence shown in ~~Figure 1~~ Figure 1A-C (SEQ ID NO:1) or of the coding sequence of the deposited clone. As known in the art, an allelic variant is an alternate form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide.

Please replace paragraph **[0035]** with the following:

**[0035]** The present invention further relates to polynucleotides which hybridize to the hereinabove-described sequences if there is at least 70%, preferably at least 90%, and more preferably at least 95% identity between the sequences. The present invention particularly relates to polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which either retain substantially the same biological function or activity as the mature polypeptide encoded by the cDNAs of ~~Figure 1~~ Figure 1A-C (SEQ ID NO:1) or the deposited cDNA(s), i.e. function as a soluble PAF receptor by retaining the ability to bind the ligands for the receptor even though the polypeptide does not function as a membrane bound PAF receptor, for example, by eliciting a second messenger response.

Please replace paragraphs **[0039-0040]** with the following:

**[0039]** The present invention further relates to a PAF receptor polypeptide which has the deduced amino acid sequence of ~~Figure 1~~ Figure 1A-C (SEQ ID NO:2) or which has the amino acid sequence encoded by the deposited cDNA, as well as fragments, analogs and derivatives of such polypeptide.

**[0040]** The terms "fragment," "derivative" and "analog" when referring to the polypeptide of ~~Figure 1~~ Figure 1A-C (SEQ ID NO:2) or that encoded by the deposited cDNA, means a polypeptide which either retains substantially the same biological function or activity as such polypeptide, i.e. functions as a PAF receptor, or retains the ability to bind the ligand for the receptor even though the polypeptide does not function as a G-protein PAF receptor, for example, a soluble form of the receptor.

Please replace paragraph **[0042]** with the following:

**[0042]** The fragment, derivative or analog of the polypeptide of ~~Figure 1~~ Figure 1A-C (SEQ ID NO:2) or that encoded by the deposited cDNA may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide which are employed for purification of the mature polypeptide or a proprotein sequence or (v) one in which a fragment of the polypeptide is soluble, i.e. not membrane bound, yet still binds ligands to the membrane bound receptor. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

***Amendments to the Figures***

Please replace the drawings of Figures 1 and 2 (3 sheets) as originally filed with the Replacement Drawings of Figures 1A-C and 2 (4 sheets) submitted herewith. Please note that in the Replacement Drawings, Figure 1 is labeled as Figure1A-C in accordance with 37 CFR 1.84(U)(1). No new matter is added by the amendments to Figure 1.